Loading organizations...
Key people at Spectranetics.
Spectranetics develops and manufactures specialized single-use medical devices designed for minimally invasive cardiovascular procedures. The company’s core offering centers on its proprietary excimer laser system, which utilizes excimer laser energy to precisely ablate and remove arterial plaque and pacemaker or defibrillator lead wires. This technology delivers comparatively cool ultraviolet energy in short, controlled pulses, enabling tissue removal without significant thermal damage to surrounding areas.
Founded in 1984 by Robert Golobic, PhD, and Johan Sverdrup, Spectranetics originated from the insight that excimer laser technology could be effectively leveraged to treat complex cardiovascular conditions. Their pioneering work focused on applying this unique photoablation process to address coronary lesions and other obstructions within the vascular system. The founders aimed to establish a less invasive and more precise method for these critical interventions.
Spectranetics products primarily serve cardiologists, surgeons, and other specialists within cardiac centers, facilitating advanced interventional treatments. The company focuses on expanding the utility of its excimer laser platform across multiple therapeutic applications. It continues to pursue innovations in treating various cardiovascular ailments, aiming to improve patient outcomes in complex cases involving arterial blockages and lead management.
Key people at Spectranetics.
Spectranetics Corporation, founded in 1984 and headquartered in Colorado Springs, Colorado, developed, manufactured, and distributed single-use medical devices for minimally invasive cardiovascular procedures using proprietary excimer laser technology.[1][2][3] Its products treated arterial blockages in the legs and heart, managed thrombus, and removed pacemaker and defibrillator leads, serving cardiologists, vascular specialists, and patients with peripheral arterial disease (PAD), coronary disease, and lead complications through laser catheters, aspiration tools, scoring balloons, and drug-coated balloons like the Stellarex platform.[2][3][4] The company solved challenges in crossing and ablating tough lesions—such as calcified plaque and thrombus—without significant thermal damage to surrounding tissue, enabling better blood flow restoration; it achieved revenue growth up to 47% in peak years and expanded globally to over 65 countries before its acquisition by Philips in 2017, after which it integrated into Philips' Image-Guided Therapy group.[2][3][4]
Spectranetics was founded in 1984 by Robert Golobic, PhD, and Johan Sverdrup, who envisioned using excimer laser technology to treat coronary lesions and restore blood flow, starting with limited funding and persistence that led to FDA approval for peripheral and coronary arterial disease treatments in 1993.[1][3] The company went public in 1992, raising funds by selling 2.5 million shares at $13.50 each, with the stock quickly rising above $20.[5] Early challenges included the deaths of both founders, a class-action lawsuit, and a federal investigation, alongside slow revenue growth despite the technology's promise; a turnaround began in 2011 under CEO Scott Drake and COO Shar Matin, who implemented the High Performance Management System (HPMS) to focus on "Vital Few" priorities like peripheral expansion and lead management, driving execution and culture.[1]
Spectranetics rode the wave of advancing minimally invasive cardiovascular interventions, particularly atherectomy and lead management, outpacing market growth through laser innovation amid rising PAD prevalence and aging populations.[3] Its timing capitalized on FDA approvals in the 1990s and 2010s product expansions, addressing unmet needs in complex lesions where traditional tools failed, while influencing medtech by proving excimer lasers' efficacy in over 65 countries and setting benchmarks for laser-based therapies.[1][2][4] The 2017 Philips acquisition amplified its impact, integrating into a leader in image-guided therapy and accelerating adoption of tools like Stellarex amid trends in drug-coated devices and hybrid procedures.[4]
Post-2017 acquisition, Spectranetics operates as a Philips subsidiary, with its laser and VI technologies likely evolving within Philips' ecosystem of diagnostic imaging and informatics to enhance precision therapies.[2][4] Trends like AI-guided interventions, expanding PAD markets, and lead extraction demands from rising implant volumes will shape its trajectory, potentially driving further innovations in ablation and drug delivery.[3][4] Its legacy of turnaround and tech leadership positions Philips to influence cardiovascular care, tying back to the founders' vision of laser-enabled blood flow restoration now scaled globally.
